AzTrials
AzTrials

DenguePhase 1NCT04298138

Dengue 3 Human Infection Model (DENV-3)

A Phase 1 study testing Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) in people with Dengue, run by State University of New York - Upstate Medical University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated… Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Dengue
What is being tested?
Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteUnited States
Study dates
3 Aug 2020to 14 Dec 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age 18-45 at the time of consent
  • Ability and willingness to sign informed consent
  • Passing score on comprehension test of at least 75%, with up to 3 attempts
  • Available for the study period
  • Willing to use contraception for the duration of the study
  • Provide consent for release of medical history records from primary care physician, college or university, urgent care or emergency room visit

Who cannot join

  • Female: pregnant or lactating
  • Heavy menstrual bleeding within the last 6 months- menstrual periods lasting longer than 6 days, or requiring 5 or more pads or tampons per day.
  • Female subjects using an intrauterine device (IUD) or Mirena®
  • Female subjects with fibroids or uterine polyps, endometriosis, adenomyosis, and uterine scarring (e.g., after D\&C)
  • Blood tests confirming infection with human immunodeficiency virus- 1 (HIV-1), hepatitis C, hepatitis B (assessed by HbsAg) virus, or positive antibodies to the flaviviruses (FV) dengue, West Nile, Yellow Fever, Japanese encephalitis, or Zika.
  • Active Diabetes or active peptic ulcer disease (PUD)
Show all 30Show fewer
  • Chronic obstructive pulmonary disease (COPD) or coronary artery disease (CAD)
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Current, or a history of, auto-immune disease
  • History of Guillain-Barré syndrome (GBS)
  • Any history of FV infection or FV vaccination; or planned FV vaccination, outside the study protocol, during the study period
  • Diagnosis with Bipolar Disorder or Schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the subject from participating in the study.
  • Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits
  • Recent (in the past 4 weeks) travel to any dengue endemic area. These potential subjects may be eligible for enrollment a minimum of 4 weeks later
  • Any laboratory abnormalities prior to inoculation for the tests specified in Table 18 and Table 19 of the protocol, that are considered by the investigator to be clinically significant except those listed in exclusion criteria 16
  • Subjects with the following grade 2 or greater lab abnormalities: Creatinine; Liver Function Tests - ALT, AST; Hemoglobin (females and males); White Blood Cell (WBC) decrease; Platelets decreased; Prothrombin Time (PT); Partial Thromboplastin Time (PTT); Fibrinogen decrease
  • Significant screening physical examination abnormalities at the discretion of the investigator
  • Women who intend to become pregnant or men who intend to father a child during the study period (approximately 180 days)
  • Hives, shortness of breath, swelling of the lips or throat, or hospitalization related to a previous vaccination or an allergy to specific medications/animals for which antigens may be in the virus preparations to include: shellfish allergy, fetal bovine serum, L-glutamine, neomycin and streptomycin
  • Planning to donate blood in the 1 year following inoculation with dengue
  • Recent blood donation within prior 56 days of inoculation
  • Receipt of blood products or antibodies within 56 days of inoculation or during the study period
  • Participation (active or follow-up phase) or planned participation in another vaccine, drug, medical device, or medical procedure clinical trial in the 4 weeks prior to this trial, during the trial, or 6 months following inoculation in this clinical trial
  • Recent or scheduled receipt of any vaccine 4 weeks prior to or after virus inoculation
  • Beliefs that bar the administration of blood products or transfusions
  • Positive urine screen for cocaine, amphetamines, or opiates
  • Currently taking Methadone or Suboxone
  • Currently taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
  • Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
  • Chronic medical condition that, in the opinion of the investigator, impacts subject safety.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • State University of New York, Upstate Medical University (SUNY-UMU)

    Syracuse, New York, 13210

Other trials in United States

About this study

Official title: Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge - (DENV-3-LVHC) Virus Strain

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study will examine the safety and effectiveness of the Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) product and assess the ability of this virus strain to elicit an uncomplicated dengue-like illness.

Read the detailed description

Healthy subjects between 18 and 45 years old will be inoculated with Dengue 3 Live Virus Human Challenge (DENV-3-LVHC) in a dose ranging study. Subjects will be closely monitored for the first 28 days with continued follow up through 6 months. Clinical and laboratory parameters, viremia and antibody levels will be assessed. The goal is to determine the dose that produces uncomplicated dengue-like illness.

Conditions
Dengue
Being tested
Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Keywords
Dengue, Flavivirus Infections, Virus Diseases
Medical subject headings
Dengue, Flavivirus Infections, Virus Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)Biological

    Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Study groups in NCT04298138
Study groupRoleWhat they receive
Low dose DENV-3-LVHCExperimentalDengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single low dose (0.5 mL of 1.4 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Receives: Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Medium dose DENV-3-LVHCExperimentalDengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single medium dose (0.5 mL of 1.4 x 10^4 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Receives: Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
High dose DENV-3-LVHCExperimentalDengue-3 Virus-Live Virus Human Challenge (DENV-3-LVHC) single high dose (0.5 mL of 1.4 x 10^5 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
Receives: Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Abnormal Laboratory Measurements

    Total number of all abnormal labs

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  2. Intensity of Abnormal Laboratory Measurements

    Graded according clinical laboratory normals and FDA toxicity scale

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  3. Duration of Abnormal Laboratory Measurements

    Number of days of abnormal lab

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  4. Occurrence of Solicited Injection Site Symptoms

    Number of solicited symptoms

    Measured: 7 days post virus inoculation

  5. Intensity of Solicited Injection Site Symptoms

    Graded according to FDA toxicity scale

    Measured: 7 days post virus inoculation

  6. Duration of Solicited Injection Site Symptoms

    Number of days per symptom

    Measured: 7 days post virus inoculation

  7. Occurrence of Unsolicited Injection Site Symptoms

    Number of unsolicited site symptoms

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  8. Intensity of Unsolicited Injection Site Symptoms

    Graded according to FDA toxicity scale

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  9. Duration of Unsolicited Injection Site Symptoms

    Number of days per symptom

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  10. Occurrence of Solicited Systemic Symptoms

    Number of solicited systemic symptoms

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  11. Intensity of Solicited Systemic Symptoms

    Graded according to FDA toxicity scale

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  12. Duration of Solicited Systemic Symptoms

    Number of days per symptom

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  13. Occurence of Unsolicited Systemic Symptoms

    Number of unsolicited systemic symptoms

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  14. Intensity of Unsolicited Systemic Symptoms

    Graded according to FDA toxicity scale

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  15. Duration of Unsolicited Systemic Symptoms

    Number of days per symptom

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  16. Number of Serious Adverse Events

    Total number

    Measured: 28 days post virus inoculation or 7 days post hospitalization, whichever is later

  17. Number of Serious Adverse Events

    Total number

    Measured: 6 months post virus inoculation

Secondary outcomes (15)

  1. Incubation period before onset of fever

    Number of days prior to fever

    Measured: Up to 28 days post virus inoculation

  2. Viremia by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

    Levels of viremia

    Measured: Up to 28 days post virus inoculation

  3. Occurence of fever

    Defined as greater than or equal to 38°C (100.4°F) measured at least 2 times in 24 hours but not lasting more than 72 hours

    Measured: Up to 28 days post virus inoculation

  4. Occurrence of Headache

    Number of headaches

    Measured: Up to 28 days post virus inoculation

  5. Grade of Headache

    Graded according to FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

  6. Occurrence of Myalgia

    Number of reported myalgias

    Measured: Up to 28 days post virus inoculation

  7. Grade of Myalgia

    Graded according to FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

  8. Occurrence of Rash

    Number of rashes

    Measured: Up to 28 days post virus inoculation

  9. Grade of Rash

    Graded according to FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

  10. Occurrence of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]

    Number of abnormal liver function tests

    Measured: Up to 28 days post virus inoculation

  11. Grade of Abnormal Liver Function Test [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]

    Graded according clinical laboratory normals and FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

  12. Occurrence of Leukopenia

    Number of occurrences

    Measured: Up to 28 days post virus inoculation

  13. Grade of Leukopenia

    Graded according clinical laboratory normals and FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

  14. Occurrence of Thrombocytopenia

    Number of occurrences

    Measured: Up to 28 days post virus inoculation

  15. Grade of Thrombocytopenia

    Graded according clinical laboratory normals and FDA toxicity scale

    Measured: Up to 28 days post virus inoculation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2020
  2. Study start3 Aug 2020
  3. Primary completion14 Dec 2021
  4. Study completion14 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Sequential
Model description
Nine subjects will be assigned to the low dose group. Twenty-one days post inoculation, data will be reviewed for safety and if performance parameters are met. If safety profile is acceptable but performance parameters have not been met, dose escalation to the medium dose will proceed in nine additional subjects. Twenty-one days post middle dose inoculation, data will be reviewed as above and a determination will be made to proceed to the high dose.
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04298138
Sponsor's protocol ID
2019-01-UMU
Status last verified
Jun 2022
First submitted
21 Feb 2020
Last updated
11 Apr 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Wu SS, Bjerke JN, Middleton CE, Barbachano-Guerrero A, Dye JR, Worden-Sapper ER, Emerman AB, Endy TP, Thomas SJ, Waickman AT, Larremore DB, Meyerson NR, Sawyer SL. Longitudinal analysis of viral and host RNA in blood and saliva during controlled human dengue virus 3 infections. J Virol. 2026 Jun 23;100(6):e0037326. doi: 10.1128/jvi.00373-26. Epub 2026 May 14.

    PubMed 42132421

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) in people with Dengue, run by State University of New York - Upstate Medical University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Abnormal Laboratory Measurements (time frame: 28 days post virus inoculation or 7 days post hospitalization, whichever is later). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04298138, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2024; AzTrials last refreshed its copy on 30 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in